Physician profile
Amy Harrup
NPI 1033798665
$2,129.37
in general payments reported to CMS, 2019-2025
24 companies · $753 in 2025
The $753 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $177 · 2023: $444 · 2024: $642 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $570.55 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $249.78 | 2021-2025 | |
| Abbvie INC. | $212.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $148.00 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Averitas Pharma INC. | $113.94 | 2024-2025 | Qutenza |
| Pfizer INC. | $105.87 | 2021-2025 | |
| Lilly USA, LLC | $93.55 | 2023-2025 | Jardiance, Trulicity, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.18 | 2025 | Caplyta |
| Amgen INC. | $84.45 | 2024-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $78.95 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $60.33 | 2023-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $43.51 | 2021 | |
| Vanda Pharmaceuticals INC. | $42.26 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.54 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $34.63 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $27.78 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $26.44 | 2024 | Trintellix |
| Hologic Sales and Service, LLC | $21.51 | 2024 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $19.60 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $15.66 | 2023 | Contrave |
| Xeris Pharmaceuticals, INC. | $14.71 | 2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $13.86 | 2022 | |
| Verona Pharma, INC. | $13.57 | 2025 | Ohtuvayre |
| Biogen, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Harrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.